# A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

> **NCT07392320** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 142 (estimated)

## Conditions studied

- Nasopharangeal Cancer

## Interventions

- **DRUG:** TP+PD1+CCRT
- **DRUG:** PD-1 Monoclonal Antibody
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07392320
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2031-02-10
- **Final completion:** 2033-02-10
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392320, "A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07392320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*